

Ref: EPL/CS/SE/0018/2026

Date: March 02, 2026

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Press Release**

Please find enclosed herewith a Press Release titled "Emcure Pharmaceuticals and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India", which shall be released after this intimation.

You are requested to take the same on your records.

Thanking you,

**For Emcure Pharmaceuticals Limited**

**Amruta Yangelwar**  
**Company Secretary & Compliance Officer**  
**Membership Number: A25687**

## **Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251



## Emcure Pharmaceuticals and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India

**Pune, India | 2 March 2026** - Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Under the agreement, which will be effective April 1, 2026, Emcure will distribute Roche's established and globally recognised brands in the nephrology and transplant segment in India.

The agreement includes the following brands:

- **CellCept®** – A globally leading immunosuppressant and original Roche innovation, supporting organ transplants worldwide since 1995.
- **Mircera® and Neorecormon®** – Proven therapies for anemia in chronic kidney disease, including Mircera's long-acting ESA with dosing once every 2–4 weeks.

Emcure is a market leader in anemia management, and together with its subsidiaries, has a strong presence across nephrology and chronic kidney disease segments. Roche's nephrology and transplant portfolio strongly complements Emcure's existing offerings. This strategic alignment enables Emcure to expand its portfolio and bring these important medicines to a wider cross-section of patients across the country.

Commenting on the agreement, **Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals**, said, "This partnership with Roche is a natural extension of Emcure's commitment to improving outcomes in anemia and renal care. Roche's globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering optimal care to patients across India."

**Rajji Mehdwan, Managing Director & CEO, Roche India & Neighbouring Markets**, commented, "We are pleased to partner with Emcure Pharmaceuticals, a company with deep expertise and leadership in anemia management and nephrology. Through Emcure's strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche's long-standing innovations in transplant and CKD care."

The collaboration is aimed at improving patient access to proven therapies while supporting better anemia management and long-term outcomes for patients with CKD and transplant needs.

### **About Emcure Pharmaceuticals Ltd:**

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT October 2025. Emcure is present in 70+ countries globally, including Europe and Canada. For more information, visit [www.emcure.com](http://www.emcure.com)



**Emcure**<sup>®</sup>

**About Roche:**

Roche Products (India) Private Limited was incorporated in 1994 as a wholly owned subsidiary of the Roche Group, headquartered in Basel, Switzerland. Roche is the world's largest biotech company with a legacy spanning over 128 years, and a truly differentiated product portfolio in oncology, rare diseases, ophthalmology, hematology and diseases of the central nervous system. Roche is deeply committed to advancing the understanding and treatment of multiple high burden disease areas to address unmet needs and help transform patients' lives. For more information, visit [www.rocheindia.com](http://www.rocheindia.com)

**Contact**

**Emcure Pharma**

Naveen Soni

[naveen.soni@emcure.com](mailto:naveen.soni@emcure.com)

**Roche India**

Rajan S

[rajan.s@roche.com](mailto:rajan.s@roche.com)